Get the Stockscreener App
0.1832
3.43%
0.0052
Lyra Therapeutics Inc stock is traded at $0.1832, with a volume of 1.45M.
It is up +3.43% in the last 24 hours and down -24.55% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$0.178
Open:
$0.178
24h Volume:
1.45M
Relative Volume:
1.05
Market Cap:
$11.64M
Revenue:
$1.56M
Net Income/Loss:
$-62.68M
P/E Ratio:
-0.1174
EPS:
-1.56
Net Cash Flow:
$-64.35M
1W Performance:
+2.28%
1M Performance:
-24.55%
6M Performance:
-48.20%
1Y Performance:
-94.10%
1-Day Range:
$0.1745
$0.1853
1-Week Range:
$0.1625
$0.2088
52-Week Range:
$0.1625
$6.79
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| LYRA | 0.1824 | 11.64M | 1.56M | -62.68M | -64.35M | -1.56 |
| VRTX | 447.70 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.19 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.22 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
William Blair Has Positive Forecast for LYRA FY2024 Earnings - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Lyra Therapeutics stock plunges to 52-week low of $0.21 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.21 - Investing.com India
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Lyra Therapeutics Inc (LYRA) Q3 2024 Earnings: Net Loss of $11.9M, Misses EPS and Revenue Estimates - GuruFocus.com
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Lyra Therapeutics Reports Strong Safety Data, Cuts Q3 Losses by 24% as LYR-210 Advances | LYRA Stock News - StockTitan
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) PT at $4.50 - Defense World
Chronic Rhinosinusitis Market: Driving Rapid Growth with Top - openPR
Lyra Therapeutics Inc (NASDAQ: LYRA) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Lyra Therapeutics completes Phase 3 trial enrollment for CRS treatment By Investing.com - Investing.com Canada
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - The Manila Times
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Market Momentum: Lyra Therapeutics Inc (LYRA) Registers a 3.08 Increase, Closing at 0.24 - The Dwinnex
Lyra Therapeutics Inc (LYRA)’s stock price in review: A technical analysis - US Post News
Lyra Therapeutics Inc: Navigating a Turbulent Year, Up -96.61% from 52-Week Low - The InvestChronicle
Lyra Therapeutics stock plunges to 52-week low of $0.24 - Investing.com
Lyra Therapeutics stock plunges to 52-week low of $0.24 By Investing.com - Investing.com UK
What is the investor’s view on Lyra Therapeutics Inc (LYRA)? - US Post News
The time has not yet come to remove your chips from the table: Lyra Therapeutics Inc (LYRA) - SETE News
Where Do Analysts Think The Lyra Therapeutics Inc (NASDAQ: LYRA) Is Going - Stocks Register
Lyra Therapeutics Inc (LYRA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Lyra Therapeutics to Present Study Results for LYR-210 and - GlobeNewswire
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - StockTitan
Lyra Therapeutics stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.25 - Investing.com
Market Recap: Lyell Immunopharma Inc (LYEL)’s Positive Momentum, Closing at 1.46 - The Dwinnex
XTX Topco Ltd Invests $500,000 in Lindsay Co. (NYSE:LNN) - MarketBeat
Great Point Partners LLC Purchases New Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Understanding LXRX’s book value per share for better investment insights - US Post News
All You Need to Know About Tyler Technologies (TYL) Rating Upgrade to Buy - Yahoo Finance
Upward Trajectory: Lexicon Pharmaceuticals Inc (LXRX) Posts a Slidee, Closing at 1.58 - The Dwinnex
Lyell Immunopharma Inc (LYEL)’s stock price in review: A technical analysis - US Post News
Intech Investment Management LLC Buys 1,502 Shares of Tyler Technologies, Inc. (NYSE:TYL) - MarketBeat
Citigroup Acquires Substantial Stake in Syrah Resources - TipRanks
Analysts review Tyler Technologies, Inc.’s rating - Knox Daily
Ratio Examination: Lyra Therapeutics Inc (LYRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Tyler Technologies, Inc. (NYSE:TYL) Receives $582.31 Average Target Price from Analysts - MarketBeat
GILD: 3 Biotech Stocks to Watch as FDA Approvals Roll In - StockNews.com
There is no doubt that Lyra Therapeutics Inc (LYRA) ticks all the boxes. - SETE News
Renaissance Technologies LLC Acquires 291,000 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
Acadian Asset Management LLC Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Are Lyra Therapeutics Inc (LYRA) shares a good deal now? - US Post News
Ratio Revelations: Lyra Therapeutics Inc (LYRA)’s Financial Metrics in the Spotlight - The Dwinnex
The Psychology of Lyra Therapeutics Inc Inc. (LYRA) Price Performance: Understanding Market Sentiment - The InvestChronicle
Taking the lead: Lyra Therapeutics Inc (LYRA) - SETE News
Lyra Therapeutics Inc (LYRA) stock analysis: A simple moving average approach - US Post News
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Given Consensus Rating of “Hold” by Analysts - Defense World
Lyra Therapeutics Inc (LYRA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):